166 related articles for article (PubMed ID: 32550595)
1. The use of the dynamic weight bearing test to assess the effects of acute, intramuscularly administered botulinum neurotoxin type A1 in rats.
Cornet S; Périer C; Wagner S; Andriambeloson E; Pouzet B; Kalinichev M
Toxicon X; 2020 Sep; 7():100041. PubMed ID: 32550595
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the rat digit abduction score (DAS) assay: Evaluation of botulinum neurotoxin activity in the gastrocnemius lateralis, peronei, and extensor digitorum longus.
Cornet S; Périer C; Kalinichev M
Toxicon X; 2020 Jun; 6():100029. PubMed ID: 32550584
[TBL] [Abstract][Full Text] [Related]
3. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
[TBL] [Abstract][Full Text] [Related]
4. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
[TBL] [Abstract][Full Text] [Related]
5. Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.
Byun J; Kwak S; Kwon JH; Shin M; Lee DK; Rhee CH; Kang WH; Oh JW; Cruz DJM
Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737026
[TBL] [Abstract][Full Text] [Related]
6. Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.
Koizumi H; Goto S; Okita S; Morigaki R; Akaike N; Torii Y; Harakawa T; Ginnaga A; Kaji R
Front Neurol; 2014; 5():98. PubMed ID: 25002857
[TBL] [Abstract][Full Text] [Related]
7. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
[TBL] [Abstract][Full Text] [Related]
8. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
[TBL] [Abstract][Full Text] [Related]
9. Clinical duration of action of different botulinum toxin types in humans.
Eleopra R; Rinaldo S; Montecucco C; Rossetto O; Devigili G
Toxicon; 2020 May; 179():84-91. PubMed ID: 32184153
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution.
Tang-Liu DD; Aoki KR; Dolly JO; de Paiva A; Houchen TL; Chasseaud LF; Webber C
Toxicon; 2003 Oct; 42(5):461-9. PubMed ID: 14529727
[TBL] [Abstract][Full Text] [Related]
11. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats.
Shen J; Ma J; Lee C; Smith BP; Smith TL; Tan KH; Koman LA
J Orthop Res; 2006 May; 24(5):1128-35. PubMed ID: 16602109
[TBL] [Abstract][Full Text] [Related]
12. Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.
Moritz MS; Tepp WH; Inzalaco HN; Johnson EA; Pellett S
Toxicon; 2019 Sep; 167():20-28. PubMed ID: 31181297
[TBL] [Abstract][Full Text] [Related]
13. Globular chitosan prolongs the effective duration time and decreases the acute toxicity of botulinum neurotoxin after intramuscular injection in rats.
Sergeevichev DS; Krasilnikova AA; Strelnikov AG; Fomenko VV; Salakhutdinov NF; Romanov AB; Karaskov AM; Pokushalov EA; Steinberg JS
Toxicon; 2018 Mar; 143():90-95. PubMed ID: 29371111
[TBL] [Abstract][Full Text] [Related]
14. Pre-Clinical Study of a Novel Recombinant Botulinum Neurotoxin Derivative Engineered for Improved Safety.
Vazquez-Cintron E; Tenezaca L; Angeles C; Syngkon A; Liublinska V; Ichtchenko K; Band P
Sci Rep; 2016 Aug; 6():30429. PubMed ID: 27484492
[TBL] [Abstract][Full Text] [Related]
15. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
mSphere; 2016; 1(1):. PubMed ID: 27303710
[TBL] [Abstract][Full Text] [Related]
16. Bioprotection of tendon repair: adjunctive use of botulinum toxin A in Achilles tendon repair in the rat.
Ma J; Shen J; Smith BP; Ritting A; Smith TL; Koman LA
J Bone Joint Surg Am; 2007 Oct; 89(10):2241-9. PubMed ID: 17908902
[TBL] [Abstract][Full Text] [Related]
17. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.
Fredrick CM; Lin G; Johnson EA
Appl Environ Microbiol; 2017 Jul; 83(13):. PubMed ID: 28455330
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.
Elliott M; Maignel J; Liu SM; Favre-Guilmard C; Mir I; Farrow P; Hornby F; Marlin S; Palan S; Beard M; Krupp J
PLoS One; 2017; 12(10):e0185628. PubMed ID: 28982136
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Serotype CD Mosaic Botulinum Neurotoxin in Comparison with Serotype C and A.
Miyashita SI; Karatsu S; Fujiishi M; Huang IH; Nagashima Y; Morobishi T; Hosoya K; Hata T; Dong M; Sagane Y
Toxins (Basel); 2023 Feb; 15(2):. PubMed ID: 36828437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
